A new bipartisan bill to make insulin more affordable for patients could be up for a U.S. Senate vote as early as next month. There are doubts the bill will get enough Republican support to pass, however, dooming it to go the way of a recent string of failed drug-pricing bills.
Insulin has been at the heart of several recent 340B policy fights. Insulin and diabetes drug makers were among the first to impose conditions on the 340B contract pharmacy program. Three of those companies face antitrust charges over their contract pharmacy restrictions in federal district court in western New York State. The Biden administration rescinded a Trump administration rule requiring community health centers to pass along all their 340B savings on insulin to low-income patients with high-cost or no health insurance.
A new bipartisan bill to make insulin more affordable for patients could be up for a U.S. Senate vote as early as next month.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
